Cowen analyst Chris Shibutani weighed in on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), after the drug maker announced that clinical data on brigatinib, its investigational anaplastic lymphoma …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, will be presented at the International …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the launch of an inaugural awareness day for anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer …
The biotech-verse is rumbling as Cempra Inc (NASDAQ:CEMP) shares tumble despite a positive AdCom vote and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) surges ahead on …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the third quarter and first nine months of 2016.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the FDA has accepted for review the New Drug Application (NDA) for ARIAD’s investigational oral anaplastic lymphoma kinase (ALK) …
William Blair analyst Y Katherine Xu is out with a research report on shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) after having recently updated …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the publication of preclinical data on brigatinib, its investigational oral tyrosine kinase inhibitor in development for the treatment of …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares tumbled nearly 7% today, after J.
On Monday, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) presented updated clinical data from its ongoing Phase 1/2 trial on its investigational tyrosine kinase inhibitor, pipeline …
